首页> 美国卫生研究院文献>Pharmaceutics >Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors
【2h】

Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors

机译:水溶性较差的Mirabegron溶解度增强的共晶筛选及其分子间相互作用和溶解行为的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the present study, the screening of Mirabegron (MBR) co-amorphous was performed to produce water-soluble and thermodynamically stable MBR co-amorphous with the purpose of overcoming the water solubility problem of MBR. MBR is Biopharmaceutics Classification System (BCS) class II drug used for the treatment of an overreactive bladder. The co-amorphous screening was carried out by means of the vacuum evaporation crystallization technique in methanol solvent using three water-soluble carboxylic acids, characterized by a pKa difference greater than 3 with MBR such as fumaric acid (FA), l-pyroglutamic acid (PG), and citric acid (CA). Powder X-ray diffraction (PXRD) results suggested that all solid materials produced at MBR-FA (1 equivalent (eq.)/1 equivalent (eq.)), MBR-PG (1 eq./1 eq.), and MBR-CA (1 eq./1 eq.) conditions were amorphous state solid materials. Furthermore, by means of solution-state nuclear magnetic resonance (NMR) (1H, 13C, and 2D) and attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, we could assess that MBR and carboxylic acid molecules were linked via ionic interactions to produce MBR co-amorphous. Besides, solid-state cross polarization (CP)/magic angle spinning (MAS) 13C-NMR analysis was conducted for additional assessment of MBR co-amorphous. Afterwards, dissolution tests of MBR co-amorphouses, MBR crystalline solid, and MBR amorphous were carried out for 12 h to evaluate and to compare their solubilities, dissolution rates, and phase transformation phenomenon. Here, the results suggested that MBR co-amorphouses displayed more than 57-fold higher aqueous solubility compared to MBR crystalline solid, and PXRD monitoring result suggested that MBR co-amorphouses were able to maintain their amorphous state for more than 12 h. The same results revealed that MBR amorphous exhibited increased solubility of approximatively 6.7-fold higher compared to MBR crystalline solid. However, the PXRD monitoring result suggested that MBR amorphous undergo rapid phase transformation to crystalline form in just 35 min and that within an hour all MBR amorphous are completely converted to crystalline solid. Accordingly, the increase in MBR co-amorphous’ solubility was attributed to the presence of ionic interactions in MBR co-amorphous molecules. Moreover, from the differential scanning calorimetry (DSC) monitoring results, we predicted that the high glass transition temperature (Tg) of MBR co-amorphous compared to MBR amorphous was the main factor influencing the phase stability of MBR co-amorphous.
机译:在本研究中,为了克服MBR的水溶性问题,进行了Mirabegron(MBR)共非晶的筛选,以生产水溶性和热力学稳定的MBR共非晶。 MBR是用于治疗膀胱过度反应症的II类生物制药分类系统药物。通过真空蒸发结晶技术在甲醇溶剂中使用三种水溶性羧酸进行共非晶筛选,其特征在于与MBR的富马酸(FA),1-焦谷氨酸( PG)和柠檬酸(CA)。粉末X射线衍射(PXRD)结果表明,所有固体材料均以MBR-FA(1当量(eq。)/ 1当量(eq。)),MBR-PG(1eq./1eq。)和MBR产生-CA(1 eq./1 eq。)条件为非晶态固体材料。此外,借助溶液状态核磁共振(NMR)( 1 H, 13 C和2D)和衰减全反射傅立叶变换红外光谱(ATR-FTIR)光谱学上,我们可以评估MBR和羧酸分子是通过离子相互作用相互连接产生MBR共非晶的。此外,进行了固态交叉极化(CP)/魔角旋转(MAS) 13 C-NMR分析,以进一步评估MBR共非晶态。然后,对MBR共无定形物,MBR结晶固体和MBR无定形进行溶出度测试12小时,以评估并比较它们的溶解度,溶出速率和相变现象。在此,结果表明,MBR共无定形物的水溶性比MBR结晶固体高出57倍以上,而PXRD监测结果表明MBR共无定形物能够保持其非晶态超过12小时。相同的结果表明,与MBR结晶固体相比,MBR无定形的溶解度提高了约6.7倍。但是,PXRD监测结果表明,MBR非晶态仅在35分钟内就经历了快速的相转化为结晶形式,并且在一个小时内,所有MBR非晶态都完全转化为结晶固体。因此,MBR共非晶的溶解度增加归因于MBR共非晶分子中离子相互作用的存在。此外,根据差示扫描量热法(DSC)的监测结果,我们预测与MBR非晶态相比,MBR非晶态的高玻璃化转变温度(Tg)是影响MBR非晶态相稳定性的主要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号